Navigation Links
Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
Date:10/16/2009

NEW YORK, Oct. 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities

http://www.reportlinker.com/p0155347/Reportlinker-Adds-The-Middle-Eastern-Pharmaceutical-Market-Outlook-To-2014-Policy-environment-market-structure-competitive-landscape-growth-opportunities.html

Introduction

Recently, the countries of the Middle East have become increasingly important markets as a result of substantial investment in both the private and public sectors, introduction of mass health insurance and several moves to liberalize national economies. Egypt, Turkey, Saudi Arabia, Israel, Jordan, United Arab Emirates, Lebanon and Kuwait are the major countries of the Middle East with a total population of around 213m. Turkey, one of the key pharmerging markets of the world, is a strong proponent of liberal trade and investment policies. It has an open trading system, especially with countries in the EU, with which it forged a customs union agreement in 1996. Among the Gulf countries, Saudi Arabia is considered as the most attractive healthcare market in the Gulf which is mainly because of its rapidly growing population, enormous economic resources.

The Middle East pharmaceutical market is diverse, with a significant presence of leading global players alongside domestic pharmaceutical companies such as Ibrahim, Bilim and Deva. The market dynamics are further shaped by the presence of several leading suppliers of branded generics and APIs (active pharmaceutical ingredients) such as Teva, Hikma, Ibrahim, etc. Although, Middle East countries were a late entrant to the biotech sector, countries like Turkey, Saudi Arabia, UAE and Israel has made a dramatic progress in recent years, which was mainly due to several government initiatives. Moreover, several public-private partnerships also boosted the growth of pharmaceutical sector in the Middle East region.

Key findings

  • The Middle East pharmaceutical market was valued at $14.8bn in 2008, registering a y-o-y sales growth of 12.6%, and is forecast to return at a CAGR of 8.1% between 2008 and 2014 to reach a total value of 23.5bn in 2014. The general anti-infective market is expected to generate the highest sales of $3.9bn in 2014, followed by alimentary canal & metabolic disorders at $3.7bn.
  • General anti-infectives, alimentary canal & metabolism and cardiovascular disorders remained as top selling therapeutic categories in the Middle East, while registering 2008 sales of $2.6bn, $2.3bn and $1.9bn respectively.
  • The leading brands in the Middle East pharmaceutical market had a predominance of respiratory and cardiovascular drugs. However, the top 10 brands constituted a very small fraction of the Middle East market, with other drugs making up 94.1% of the total market in 2008. GSK's asthma and COPD drug Seretide dominated the market with 2008 sales of $134m, a strong growth of 21% over 2007.

Key features of this report

  • The macroeconomic environment in the Middle East countries includes the population profile, disease burden and macroeconomic comparison (involving economic landscape and healthcare spending) for all the major Middle East markets
  • Profiles of the healthcare system across the 8 markets (Egypt, Turkey, Saudi Arabia, Israel, Jordan, UAE, Lebanon and Kuwait) of the Middle East region
  • Overview of key recent events in the Middle East pharmaceutical market that have impacted treatment trends and sales potential across all the Middle East countries
  • Forecasts and analysis of the leading products in the Middle East market over the period 2008-14 spread across the major indications and classes of treatments

Use this report to

  • Develop insights for the Middle East pharmaceutical market, pricing & regulation and detailed epidemiological status of the common indications/risk factors across 8 major countries of the Middle East region
  • Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive challenges in the Middle East market place
  • Gain up-to-date competitive intelligence across a wide-range of marketed products, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Middle East market

Discover

  • What will be the major growth indications in the Middle East pharmaceutical market over the period 2008-14?
  • Which companies (both multinational and domestic) will become the key players in the Middle East market over the period 2008-14?
  • Which products will be impacted by generic competition over the period 2008-14?
  • Which products will be the future growth drivers for the Middle East pharmaceutical market?
  • Which therapeutic categories are predicted to offer substantial commercial opportunity in the forecast period from 2008-14?

Table of Contents

The Middle Eastern Pharmaceutical Market Outlook to 2014

Executive Summary 12

The macroeconomic environment in the Middle East 12

Healthcare systems in the Middle East 13

Pharmaceutical market analysis of the Middle East 14

Competitive landscape of the Middle Eastern pharmaceutical market 15

Scope and Methodology 18

Scope 18

Methodology 18

Chapter 1 The macroeconomic environment in the Middle East 20

Summary 20

Introduction 21

Population profile 22

Disease burden 24

Macroeconomic comparison of the Middle East 30

Economic landscape of key Middle Eastern countries 32

Egypt 32

Turkey 33

Saudi Arabia 34

Israel 35

Jordan 36

Lebanon 38

Kuwait 38

Healthcare spending 39

Chapter 2 Healthcare systems in the Middle East 42

Summary 42

Introduction 43

Profiles of the healthcare systems across Middle Eastern countries 43

Egypt 43

Healthcare system 43

Intellectual property rights 44

Pricing and reimbursement 45

Key recent events 46

Turkey 47

Healthcare system 47

Intellectual property rights 49

Pricing and reimbursement 50

Key recent events 52

Saudi Arabia 53

Healthcare system 53

Intellectual property rights 54

Pricing and reimbursement 55

Key recent events 57

Israel 58

Healthcare system 58

Intellectual property rights 58

Pricing and reimbursement 59

Key recent events 61

Jordan 62

Healthcare system 62

Intellectual property rights 63

Pricing and reimbursement 63

Key recent events 64

Healthcare system 65

Intellectual property rights 66

Pricing and reimbursement 67

Key recent events 68

Lebanon 68

Healthcare system 68

Intellectual property rights 69

Pricing and reimbursement 70

Key recent events 71

Kuwait 71

Healthcare system 71

Intellectual property rights 72

Pricing and reimbursement 72

Key recent events 73

Chapter 3 Pharmaceutical Market analysis in the Middle East 76

Summary 76

Introduction 77

Pharmaceutical market overview 77

Therapy area analysis 80

Therapy area sales forecast 81

Therapy area analysis by country 82

Egypt 82

Turkey 85

Saudi Arabia 88

Israel 90

Jordan 93

Lebanon 97

Kuwait 100

Leading brands analysis 103

Seretide (GSK) 104

Lipitor (Pfizer) 104

Augmentin (GSK/MUP) 104

Glivec (Novartis) 105

Co-Diovan (Novartis) 105

Spiriva (Boehringer Ingelheim) 106

Plavix (Sanofi-Aventis) 106

Cipralex (Lundbeck) 107

Lansor (Sanovel) 107

Symbicort (AstraZeneca) 108

Leading brands sales forecast 108

Key brand analysis by country 110

Egypt 110

Flumox and Cefotax (Eipico) 110

Amaryl (Sanofi-Aventis) 111

Cataflam (Novartis) 111

Augmentin (MUP) 111

Turkey 112

Foradil Combi (Novartis) 113

Taxotere (Sanofi-Aventis) 113

Herceptin (Roche) 114

Saudi Arabia 114

Augmentin (GSK) 115

Snafi (Spimaco) 116

Viagra (Pfizer) 116

Nexium (AstraZeneca) 116

Israel 116

Norditropin (Novo Nordisk) 117

Seretide (GSK) 118

Tritace (Sanofi-Aventis) 118

Jordan 118

Amoclan (Hikma) 119

Similac Gain and Similac Advance (Abbott Nutrition) 119

Cerelac (Nestle) 120

United Arab Emirates 121

Cialis (Eli Lilly) 121

Plavix (Sanofi-Aventis) 122

Zinnat (GSK) 122

Lebanon 122

Pariet (J&J) 123

Concor (Merck KGaA) 123

Crestor (AstraZeneca) 124

Kuwait 124

Rocephin (Roche) 125

Xenical (Roche) 125

Yasmin (Bayer) 126

Chapter 4 Competitive landscape of the Middle Eastern pharmaceutical market 128

Summary 128

Introduction 129

Leading players 129

Analysis of key players in the Middle East 133

Novartis 133

Overview 133

Sales focus by leading drug class 133

Marketed product portfolio 135

Novartis' pipeline focus 138

Strategic growth analysis 139

Overview 142

Sales focus by leading drug class 142

Marketed product portfolio 144

GSK's pipeline focus 146

Strategic growth analysis 147

Sanofi-Aventis 150

Overview 150

Sales focus by leading drug class 150

Marketed product portfolio 152

Sanofi-Aventis pipeline focus 154

Strategic growth analysis 155

Pfizer 157

Overview 157

Sales focus by leading drug class 157

Marketed product portfolio 159

Pfizer's pipeline focus 161

Strategic growth analysis 162

Ibrahim 165

Overview 165

Sales focus by leading drug class 166

Marketed product portfolio 167

Ibrahim's pipeline focus 169

Strategic growth analysis 169

Leading players analysis by country 171

Egypt 171

Turkey 172

Saudi Arabia 174

Israel 176

Jordan 178

Lebanon 182

Kuwait 183

Chapter 5 Appendix 186

Anatomical therapeutic classification (ATC) 186

A: Alimentary tract and metabolism 186

B: Blood and blood-forming organs 186

C: Cardiovascular system 186

D: Dermatologicals 187

G: Genitourinary system and sex hormones 187

H: Systemic hormonal preparations 187

J: General anti-infectives systemic 187

K: Hospital solutions 187

L: Antineoplastic and immunomodulating agents 187

M: Musculoskeletal system 188

N: Nervous system 188

P: Parasitology 188

R: Respiratory system 188

S: Sensory organs 188

T: Diagnostic agents 188

V: Various 189

Forecast factors 189

Glossary 190

Index 191

List of Figures

Figure 1.1: GDP composition by sector in key Middle East countries, 2008 32

Figure 1.2: Comparison of healthcare expenditure across major Middle Eastern countries 39

Figure 3.3: Middle East pharmaceutical market share by countries, 2008 79

Figure 3.4: Top 10 drug classes in the Egyptian pharmaceutical market, 2008 ($m) 85

Figure 3.5: Top 10 drug classes in the Turkish pharmaceutical market, 2008 ($m) 87

Figure 3.6: Top 10 drug classes in the Saudi Arabian pharmaceutical market, 2008 ($m) 90

Figure 3.7: Top 10 drug classes in the Israel pharmaceutical market, 2008 ($m) 92

Figure 3.8: Top 10 drug classes in the Jordanian pharmaceutical market, 2008 ($m) 94

Figure 3.9: Top 10 drug classes in the UAE pharmaceutical market, 2008 ($m) 97

Figure 3.10: Top 10 drug classes in the Lebanese pharmaceutical market, 2008 ($m) 100

Figure 3.11: Top 10 drug classes in the Kuwaiti pharmaceutical market, 2008 ($m) 102

Figure 4.12: Market share of top 10 and other players in the Middle East pharmaceutical market, 2008 132

Figure 4.13: Novartis' Middle East pharmaceutical market sales by therapy area, 2008 134

Figure 4.14: GSK's Middle East pharmaceutical market sales by therapy area, 2008 143

Figure 4.15: Sanofi-Aventis' Middle East pharmaceutical market sales by therapy area, 2008 151

Figure 4.16: Pfizer's Middle East pharmaceutical market sales by therapy area, 2008 158

Figure 4.17: Ibrahim's Middle East pharmaceutical market sales by therapy area, 2008 166

List of Tables

Table 1.1: Demographic profile of key Middle East countries 23

Table 1.2: Forecast epidemiology of common risk factors in Egypt, 2008-14 25

Table 1.3: Forecast epidemiology of common risk factors in Turkey, 2008-14 25

Table 1.4: Forecast epidemiology of common risk factors in Saudi Arabia, 2008-14 26

Table 1.5: Forecast epidemiology of common risk factors in Israel, 2008-14 27

Table 1.6: Forecast epidemiology of common risk factors in Jordan, 2008-14 27

Table 1.7: Forecast epidemiology of common risk factors in UAE, 2008-14 28

Table 1.8: Forecast epidemiology of common risk factors in Lebanon, 2008-14 29

Table 1.9: Forecast epidemiology of common risk factors in Kuwait, 2008-14 30

Table 1.10: Key economic metrics of Middle East countries, 2008 31

Table 3.11: Pharmaceutical sales in major Middle East countries, 2008 78

Table 3.12: Middle East pharmaceutical sales by therapy area, 2008 81

Table 3.13: Middle East pharmaceutical market sales forecast by ATC code, 2008-14 82

Table 3.14: Egypt's pharmaceutical market by therapy area sales, 2008 83

Table 3.15: Turkey's pharmaceutical market by therapy area sales, 2008 86

Table 3.16: Saudi Arabia's pharmaceutical market break-down by therapy area sales, 2008 89

Table 3.17: Israel's pharmaceutical market by therapy area sales, 2008 91

Table 3.18: Jordan's pharmaceutical market breakdown by therapy area sales, 2008 93

Table 3.19: UAE's pharmaceutical market by therapy area sales, 2008 96

Table 3.20: Lebanon's pharmaceutical market by therapy area sales, 2008 98

Table 3.21: Kuwait's pharmaceutical market by therapy area sales, 2008 101

Table 3.22: Leading brands in the Middle East pharmaceutical market, 2008 103

Table 3.23: Leading brand sales forecast, 2008-14 109

Table 3.24: Leading brands in the Egyptian pharmaceutical market, 2008 110

Table 3.25: Leading brands in the Turkish pharmaceutical market, 2008 112

Table 3.26: Leading brands in the Saudi Arabian pharmaceutical market, 2008 115

Table 3.27: Leading brands in the Israeli pharmaceutical market, 2008 117

Table 3.28: Leading brands in the Jordanian pharmaceutical market, 2008 119

Table 3.29: Leading brands in the UAE pharmaceutical market, 2008 121

Table 3.30: Leading brands in the Lebanese pharmaceutical market, 2008 123

Table 3.31: Leading brands in the Kuwaiti pharmaceutical market, 2008 125

Table 4.32: Leading companies in the Middle East pharmaceutical market, 2008 130

Table 4.33: Novartis' leading brands in the Middle East market, 2008 136

Table 4.34: GSK's leading brands in the Middle East market, 2008 145

Table 4.35: Sanofi-Aventis' leading brands in the Middle East market, 2008 152

Table 4.36: Pfizer's leading brands in the Middle East market, 2008 159

Table 4.37: Ibrahim's leading brands in the Middle East market, 2008 168

Table 4.38: Leading companies in the Egyptian pharmaceutical market, 2008 171

Table 4.39: Leading companies in the Turkish pharmaceutical market, 2008 173

Table 4.40: Leading companies in the Saudi Arabian pharmaceutical market, 2008 175

Table 4.41: Leading companies in the Israeli pharmaceutical market, 2008 177

Table 4.42: Leading companies in the Jordanian pharmaceutical market, 2008 179

Table 4.43: Leading companies in the UAE pharmaceutical market, 2008 181

Table 4.44: Leading companies in the Lebanese pharmaceutical market, 2008 182

Table 4.45: Leading companies in the Kuwaiti pharmaceutical market, 2008 184

To order this report:

Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities

http://www.reportlinker.com/p0155347/Reportlinker-Adds-The-Middle-Eastern-Pharmaceutical-Market-Outlook-To-2014-Policy-environment-market-structure-competitive-landscape-growth-opportunities.html

More market research reports here!

    Contact:
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
2. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
3. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
4. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
5. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
6. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
7. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
8. Reportlinker Adds US Disposable Medical Supplies Market Report
9. OhioHealth Installs Newest Version of Sysmexs Hematology Middleware, Sysmex WAM(TM) 4.0
10. Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimers Disease
11. New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... Feb. 11, 2016 Potrero Medical, Inc., the developer ... announce the appointment of George M. Rapier, III , ... Antonio, TX , WellMed is one of the nation,s ... and HMO members in Texas and ... out of his own internal medicine practice, he has been ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... Atlanta, GA (PRWEB) , ... February 12, 2016 ... ... and relationship-marketing firm announced that nominations have closed for the ISE Southeast Awards ... categories will be announced at the ISE® Southeast Executive Forum and Awards Gala ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Every winter, someone ... This winter the West Penn Burn Center, part of the Allegheny Health ... to bring you the “Space Heaters Need Space” campaign. , “Space ...
(Date:2/12/2016)... ... ... The Jones Agency, a family owned insurance company with offices serving Arlington, Dallas, ... with the Tarrant Area Food Bank in the hopes of alleviating hunger for nearby ... Tarrant County Food Bank offers hope and security to the one in six Texas ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young Asset Protection, a full ... of the latest charity campaign in their community enrichment program. Art Expression utilizes ... worthy cause are currently being accepted at: http://artexpressioninc.org/ . , Art Expression ...
Breaking Medicine News(10 mins):